Paper Details

  1. Home
  2. Paper Details

Activity of Procanbid, procainamide twice-daily formulation, to suppress ventricular premature depolarizations. The Study Group Investigators.

Author: HaberH E, KerinN Z, MeengsW L, SalernoD, SingerR M, TimmisG C

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A twice-daily formulation of procainamide was found to be as effective as the current four-times-daily formulation in suppressing ventricular premature depolarizations. The new formulation showed similar safety and tolerability, with only a low proarrhythmic rate.
Paper Details　
Original Abstract of the Article :
Procainamide is a class IA antiarrhythmic drug indicated for the treatment of life-threatening or symptomatic ventricular arrhythmias. The current sustained-release formulation requires 6-hour dosing (qid). To improve patient compliance, a new sustained-release formulation for twice-daily (bid) admi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1023/a:1007736931662

データ提供：米国国立医学図書館（NLM）

Twice-Daily Procainamide: A New Formulation for the Treatment of Ventricular Arrhythmias

The treatment of ventricular arrhythmias, characterized by abnormal heart rhythms originating in the ventricles, often involves the use of antiarrhythmic drugs like procainamide. This research explores a new, twice-daily formulation of procainamide, Procanbid, aiming to improve patient compliance and reduce the frequency of dosing. The study compares the effectiveness and safety of this new formulation to the existing four-times-daily formulation, providing valuable insights into its potential clinical utility.

Twice-Daily Procainamide: Comparable Efficacy and Improved Compliance

The study reveals that the twice-daily formulation of procainamide is comparable in efficacy to the existing four-times-daily formulation in suppressing ventricular premature depolarizations (VPDs). This finding holds significant implications for patient compliance, as a twice-daily regimen can make it easier for individuals to adhere to their prescribed treatment plan. The improved compliance can ultimately lead to better control of arrhythmias and improved patient outcomes.

Finding the Right Balance: Balancing Efficacy and Tolerability

While the study highlights the comparable efficacy of the twice-daily formulation, it also acknowledges the potential for side effects. The authors emphasize the importance of careful monitoring and dose adjustments to ensure the optimal balance between efficacy and tolerability. Understanding the potential risks and benefits is crucial for individualizing treatment approaches and maximizing the positive outcomes for each patient.

Dr.Camel's Conclusion

This research brings us closer to a more patient-friendly approach to treating ventricular arrhythmias. The twice-daily formulation of procainamide offers comparable efficacy to the existing four-times-daily regimen, potentially enhancing patient compliance and leading to better control of arrhythmias. By weighing the potential benefits against the risks, healthcare professionals can make informed decisions to optimize treatment outcomes for individuals with ventricular arrhythmias.

Date :
  1. Date Completed 1997-07-21
  2. Date Revised 2019-09-14
Further Info :

Pubmed ID

9140693

DOI: Digital Object Identifier

10.1023/a:1007736931662

Related Literature

Article Analysis
・Side Effects of procainamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.